{
  "Cluster": "12",
  "CandidateSubtype": "fetal",
  "TopGenes": [
    "FGA",
    "FGB",
    "FGG",
    "CPS1",
    "C3",
    "HP",
    "RELN",
    "FMO5",
    "PGC",
    "PAH",
    "FN1",
    "F5",
    "ATP1B1",
    "AFM",
    "A2M",
    "BHMT",
    "GLUL",
    "CFH",
    "ALDH2",
    "TMBIM6"
  ],
  "ProliferationScore": "0.115 (low)",
  "StemnessScore": "0.064 (low)",
  "ImmuneScore": "0.215 (low)",
  "PrognosticScore": "0.377 (intermediate)",
  "SupportingEvidence": [
    "Strong hepatocyte secretory program: fibrinogen chains (FGA/FGB/FGG), coagulation factor F5, AFM, A2M, HP, complement factors (C3/CFH).",
    "Metabolic enzyme profile typical of differentiated hepatocytes: CPS1, BHMT, PAH, GLUL, ALDH2, FMO5.",
    "Co-expression of zonation markers CPS1 (periportal) and GLUL (pericentral) seen in fetal-like hepatoblastoma clusters with hepatocyte differentiation.",
    "Absence of classic embryonal/progenitor markers (e.g., EPCAM, KRT19, DLK1, MKI67) among top genes."
  ],
  "SuggestedExperiments": [
    "IHC/IF for CPS1, GLUL, HepPar-1; and counterstain for AFP, EPCAM, KRT19, DLK1 to exclude embryonal/ductal features.",
    "Assess beta-catenin pathway (nuclear CTNNB1 staining; CTNNB1/AXIN1 sequencing) given GLUL upregulation.",
    "Functional assays of hepatocyte differentiation (urea cycle activity via CPS1, glutamine synthetase activity).",
    "Spatial transcriptomics or RNA ISH to localize CPS1/GLUL and fibrinogen gene expression within tumor regions.",
    "Secretome/proteomics or ELISA for fibrinogen, A2M, AFM to validate hepatocyte secretory phenotype.",
    "Pathology review for fetal histology (polygonal cells with low mitotic index) and exclude mixed patterns."
  ]
}